Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5- fluorouracil (5-FU)

John Nemunaitis, John Cox, Wally Meyer, Alice Courtney, Gabriele Mues

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: To determine the prognostic role of a K-ras mutation in tumor tissue of patients with refractory colon cancer who received irinotecan hydrochloride (CPT-11). Methods: DNA was extracted from paraffin-stored tumor tissue of 35 patients with progressive colon cancer failing treatment with 5- fluorouracil who subsequently received CPT-11 (100 mg/m2 i.v. per week x 4 weeks with 2 weeks off per course). The first exon of the K-ras gene was amplified by polymerase chain reaction by using K-ras-specific primers followed by mutant enrichment sequencing. Survival differences of patients with a K-ras mutation were compared with those of patients with a normal K- ras status. Results: A total of 21 patients had a normal K-ras sequence and 14 patients had a K-ras mutation [GAT, n = 7; TGT, n = 3; and GCT, AGT, GTT, GAC (codon 13), n = 1 each]. Median survival of patients with a normal ras sequence from time of treatment with CPT-11 was 332 days compared with 169 days for patients with a K-ras mutation (p = 0.0036). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Conclusion: Determination of the presence of a K-ras mutation may predict survival in patients with progressive colon cancer after treatment with 5-fluorouracil who receive CPT-11.

Original languageEnglish (US)
Pages (from-to)527-529
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number5
DOIs
StatePublished - Oct 1 1997

Fingerprint

irinotecan
Fluorouracil
Colonic Neoplasms
Mutation
Therapeutics
Survival
Neoplasms
ras Genes

Keywords

  • 5-Fluorouracil
  • Colon cancer
  • CPT-11
  • Irinotecan hydrochloride
  • K-ras mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5- fluorouracil (5-FU). / Nemunaitis, John; Cox, John; Meyer, Wally; Courtney, Alice; Mues, Gabriele.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 5, 01.10.1997, p. 527-529.

Research output: Contribution to journalArticle

@article{19a027d3b75c4f9290056c80c28ac082,
title = "Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5- fluorouracil (5-FU)",
abstract = "Objective: To determine the prognostic role of a K-ras mutation in tumor tissue of patients with refractory colon cancer who received irinotecan hydrochloride (CPT-11). Methods: DNA was extracted from paraffin-stored tumor tissue of 35 patients with progressive colon cancer failing treatment with 5- fluorouracil who subsequently received CPT-11 (100 mg/m2 i.v. per week x 4 weeks with 2 weeks off per course). The first exon of the K-ras gene was amplified by polymerase chain reaction by using K-ras-specific primers followed by mutant enrichment sequencing. Survival differences of patients with a K-ras mutation were compared with those of patients with a normal K- ras status. Results: A total of 21 patients had a normal K-ras sequence and 14 patients had a K-ras mutation [GAT, n = 7; TGT, n = 3; and GCT, AGT, GTT, GAC (codon 13), n = 1 each]. Median survival of patients with a normal ras sequence from time of treatment with CPT-11 was 332 days compared with 169 days for patients with a K-ras mutation (p = 0.0036). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Conclusion: Determination of the presence of a K-ras mutation may predict survival in patients with progressive colon cancer after treatment with 5-fluorouracil who receive CPT-11.",
keywords = "5-Fluorouracil, Colon cancer, CPT-11, Irinotecan hydrochloride, K-ras mutation",
author = "John Nemunaitis and John Cox and Wally Meyer and Alice Courtney and Gabriele Mues",
year = "1997",
month = "10",
day = "1",
doi = "10.1097/00000421-199710000-00020",
language = "English (US)",
volume = "20",
pages = "527--529",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5- fluorouracil (5-FU)

AU - Nemunaitis, John

AU - Cox, John

AU - Meyer, Wally

AU - Courtney, Alice

AU - Mues, Gabriele

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Objective: To determine the prognostic role of a K-ras mutation in tumor tissue of patients with refractory colon cancer who received irinotecan hydrochloride (CPT-11). Methods: DNA was extracted from paraffin-stored tumor tissue of 35 patients with progressive colon cancer failing treatment with 5- fluorouracil who subsequently received CPT-11 (100 mg/m2 i.v. per week x 4 weeks with 2 weeks off per course). The first exon of the K-ras gene was amplified by polymerase chain reaction by using K-ras-specific primers followed by mutant enrichment sequencing. Survival differences of patients with a K-ras mutation were compared with those of patients with a normal K- ras status. Results: A total of 21 patients had a normal K-ras sequence and 14 patients had a K-ras mutation [GAT, n = 7; TGT, n = 3; and GCT, AGT, GTT, GAC (codon 13), n = 1 each]. Median survival of patients with a normal ras sequence from time of treatment with CPT-11 was 332 days compared with 169 days for patients with a K-ras mutation (p = 0.0036). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Conclusion: Determination of the presence of a K-ras mutation may predict survival in patients with progressive colon cancer after treatment with 5-fluorouracil who receive CPT-11.

AB - Objective: To determine the prognostic role of a K-ras mutation in tumor tissue of patients with refractory colon cancer who received irinotecan hydrochloride (CPT-11). Methods: DNA was extracted from paraffin-stored tumor tissue of 35 patients with progressive colon cancer failing treatment with 5- fluorouracil who subsequently received CPT-11 (100 mg/m2 i.v. per week x 4 weeks with 2 weeks off per course). The first exon of the K-ras gene was amplified by polymerase chain reaction by using K-ras-specific primers followed by mutant enrichment sequencing. Survival differences of patients with a K-ras mutation were compared with those of patients with a normal K- ras status. Results: A total of 21 patients had a normal K-ras sequence and 14 patients had a K-ras mutation [GAT, n = 7; TGT, n = 3; and GCT, AGT, GTT, GAC (codon 13), n = 1 each]. Median survival of patients with a normal ras sequence from time of treatment with CPT-11 was 332 days compared with 169 days for patients with a K-ras mutation (p = 0.0036). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Conclusion: Determination of the presence of a K-ras mutation may predict survival in patients with progressive colon cancer after treatment with 5-fluorouracil who receive CPT-11.

KW - 5-Fluorouracil

KW - Colon cancer

KW - CPT-11

KW - Irinotecan hydrochloride

KW - K-ras mutation

UR - http://www.scopus.com/inward/record.url?scp=0030839388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030839388&partnerID=8YFLogxK

U2 - 10.1097/00000421-199710000-00020

DO - 10.1097/00000421-199710000-00020

M3 - Article

C2 - 9345343

AN - SCOPUS:0030839388

VL - 20

SP - 527

EP - 529

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -